Heres a simple breakdown Ozempic (Semaglutide) Class: GLP-1 receptor agonist Helps: Control blood sugar + reduce CV risk Weight loss: Significant (~15%) Once weekly injection Common effects: Nausea, vomiting, diarrhea Extra: Proven cardiovascular benefit in T2D Trulicity (Dulaglutide) Class: GLP-1 receptor agonist Helps: Blood sugar control + CV protection Approved for children 10+ with T2D Weight loss: Modest Once weekly prefilled pen Common effects: GI discomfort Mounjaro (Tirzepatide) Class: Dual GIP + GLP-1 receptor agonist Helps: Powerful glucose control Weight loss: Highest among the three Once weekly (dose escalation) Common effects: GI symptoms (especially during dose increase) All carry a warning for possible thyroid C-cell tumor risk (avoid in patients with MEN2 or medullary thyroid carcinoma history)
Currently, only Novo Nordisk is authorized by the FDA to manufacture semaglutide and there is no generic available
If you are currently using semaglutide or tirzepatide and considering switching to this product, understand that the two categories are not equivalent
Scientists from the University of New South Wales school of chemistry analysed a sample of the STDEI GLP-1 Weight Loss Oral Liquid, which was bought from the website Maementcurves.com on 23 July, on behalf of Guardian Australia
McCoin CS, Knotts TA, Ono-Moore KD, Oort PJ, Adams SH
Are BPC-157 and TB-500 Safe